首页 > 最新文献

Neurodegenerative disease management最新文献

英文 中文
Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease. 靶向代谢性谷氨酸受体治疗帕金森病。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0016
Philippe Huot
{"title":"Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease.","authors":"Philippe Huot","doi":"10.2217/nmt-2023-0016","DOIUrl":"https://doi.org/10.2217/nmt-2023-0016","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"203-206"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10173261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. 与其他口服治疗多发性硬化症的药物相比,克拉宾片的疗效总结:来自MSBase注册表的结果。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0005
Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele LA Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon L Wong, Helmut Butzkueven

What is this summary about?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments.

What were the results?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.

What do the results mean?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.

这个总结是关于什么的?患者登记包含来自具有相同医疗状况的人的匿名数据。MSBase注册表包含来自41个国家的80,000多名多发性硬化症(MS)患者的信息。使用来自MSBase注册表的信息,GLIMPSE(在多发性硬化症中产生学习)研究观察了3475名接受克拉德滨片(Mavenclad®)治疗的多发性硬化症患者的现实结果,并与其他口服治疗进行了比较。结果如何?结果显示,服用克拉西宾片剂的患者比口服治疗的患者持续时间更长。与接受不同口腔治疗的患者相比,他们的复发(也称为症状突然发作)也更少。结果表明,与其他口服治疗多发性硬化症的药物相比,克拉宾片对多发性硬化症患者是一种有效的药物。
{"title":"A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.","authors":"Tim Spelman,&nbsp;Serkan Ozakbas,&nbsp;Raed Alroughani,&nbsp;Murat Terzi,&nbsp;Suzanne Hodgkinson,&nbsp;Guy Laureys,&nbsp;Tomas Kalincik,&nbsp;Anneke Van Der Walt,&nbsp;Bassem Yamout,&nbsp;Jeannette Lechner-Scott,&nbsp;Aysun Soysal,&nbsp;Jens Kuhle,&nbsp;Jose Luis Sanchez-Menoyo,&nbsp;Yolanda Blanco Morgado,&nbsp;Daniele LA Spitaleri,&nbsp;Vincent van Pesch,&nbsp;Dana Horakova,&nbsp;Radek Ampapa,&nbsp;Francesco Patti,&nbsp;Richard Macdonell,&nbsp;Abdullah Al-Asmi,&nbsp;Oliver Gerlach,&nbsp;Jiwon Oh,&nbsp;Ayse Altintas,&nbsp;Namita Tundia,&nbsp;Schiffon L Wong,&nbsp;Helmut Butzkueven","doi":"10.2217/nmt-2023-0005","DOIUrl":"https://doi.org/10.2217/nmt-2023-0005","url":null,"abstract":"<p><strong>What is this summary about?: </strong>Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad<sup>®</sup>) compared with other oral treatments.</p><p><strong>What were the results?: </strong>Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.</p><p><strong>What do the results mean?: </strong>The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"215-221"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9787063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a 7-day retreat for people with Parkinson's disease: a phenomenological study. 7天静修对帕金森病患者的影响:现象学研究。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0015
Lori M Bordenave, Corrine Fritcher Nelson, Becky G Farley, Tara L McIsaac

Aim: Early and ongoing access to rehabilitation and exercise may preserve functional mobility and quality of life for persons with Parkinson disease (PwP). The aim of the current study was to describe the experience of PwP who participated in a 7-day retreat. Materials & methods: A phenomenological approach was used to describe the lived experience of PwP. Results: Three themes emerged from interviews: a community of shared information where participants discussed exercising and learning with other PwP; improved control of Parkinson's disease symptoms, including performing physical tasks more easily and renewed motivation for their long-term plans for exercise because of the retreat. Conclusion: A 7-day retreat for PwP positively impacted perceived control of disease-related symptoms and intentions to continue exercise.

目的:早期和持续的康复和锻炼可以保持帕金森病(PwP)患者的功能活动和生活质量。本研究的目的是描述参加7天静修的残疾人的经验。材料与方法:采用现象学方法描述PwP的生活经验。结果:访谈中出现了三个主题:一个共享信息的社区,参与者与其他PwP讨论锻炼和学习;改善了对帕金森病症状的控制,包括更容易完成体力活动,并因为静修而重新激发了他们长期锻炼计划的动力。结论:7天的PwP治疗对疾病相关症状的感知控制和继续锻炼的意愿有积极影响。
{"title":"Impact of a 7-day retreat for people with Parkinson's disease: a phenomenological study.","authors":"Lori M Bordenave,&nbsp;Corrine Fritcher Nelson,&nbsp;Becky G Farley,&nbsp;Tara L McIsaac","doi":"10.2217/nmt-2023-0015","DOIUrl":"https://doi.org/10.2217/nmt-2023-0015","url":null,"abstract":"<p><p><b>Aim:</b> Early and ongoing access to rehabilitation and exercise may preserve functional mobility and quality of life for persons with Parkinson disease (PwP). The aim of the current study was to describe the experience of PwP who participated in a 7-day retreat. <b>Materials & methods:</b> A phenomenological approach was used to describe the lived experience of PwP. <b>Results:</b> Three themes emerged from interviews: a community of shared information where participants discussed exercising and learning with other PwP; improved control of Parkinson's disease symptoms, including performing physical tasks more easily and renewed motivation for their long-term plans for exercise because of the retreat. <b>Conclusion:</b> A 7-day retreat for PwP positively impacted perceived control of disease-related symptoms and intentions to continue exercise.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"245-255"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9800530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis. 临床研究可以告诉我们evobrutinib(一种治疗多发性硬化症的潜在药物)的安全性。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0003
Xavier Montalban, Daniel Wallace, Mark C Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H Kao, Hans Guehring

What is this summary about?: This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.

What were the results?: Evobrutinib was well-tolerated by participants in all three studies. The number of side effects reported by participants taking the medication was very similar to those reported by participants taking the placebo (a 'dummy' treatment without a real drug). The most common side effects in clinical studies were urinary tract infections, headache, swelling of the nose and throat, diarrhoea and blood markers of potential liver damage (these returned to normal once the treatment was stopped).

What do the results mean?: The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. Clinical Trial Registration: NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov).

这个总结是关于什么的?本摘要解释了最近一项调查的结果,该调查结合了来自三个临床研究的1000多人的结果,以了解evobrutinib的安全性。Evobrutinib是一种口服药物(口服),正在研究作为多发性硬化症(MS)的潜在治疗方法。这种药物也被用于类风湿关节炎(RA)和系统性红斑狼疮(SLE)。超过1000人服用依沃鲁替尼作为三个独立的二期临床研究的一部分。这些研究着眼于应该服用多少药物,药物的安全性,以及它对治疗某种疾病的效果如何。结果如何?Evobrutinib在所有三项研究中的耐受性良好。服用这种药物的参与者报告的副作用数量与服用安慰剂(一种没有真正药物的“假”治疗)的参与者报告的副作用数量非常相似。临床研究中最常见的副作用是尿路感染、头痛、鼻子和喉咙肿胀、腹泻和潜在肝损伤的血液标志物(这些在治疗停止后恢复正常)。这些结果意味着什么?三项临床研究的安全性数据令人鼓舞,可用于进一步研究evobrutinib在ms中的应用。临床试验注册号:NCT02975349(多发性硬化症)、NCT03233230(类风湿性关节炎)、NCT02975336(系统性红斑狼疮)(ClinicalTrials.gov)。
{"title":"A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.","authors":"Xavier Montalban,&nbsp;Daniel Wallace,&nbsp;Mark C Genovese,&nbsp;Davorka Tomic,&nbsp;Dana Parsons-Rich,&nbsp;Claire Le Bolay,&nbsp;Amy H Kao,&nbsp;Hans Guehring","doi":"10.2217/nmt-2023-0003","DOIUrl":"https://doi.org/10.2217/nmt-2023-0003","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.</p><p><strong>What were the results?: </strong>Evobrutinib was well-tolerated by participants in all three studies. The number of side effects reported by participants taking the medication was very similar to those reported by participants taking the placebo (a 'dummy' treatment without a real drug). The most common side effects in clinical studies were urinary tract infections, headache, swelling of the nose and throat, diarrhoea and blood markers of potential liver damage (these returned to normal once the treatment was stopped).</p><p><strong>What do the results mean?: </strong>The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. <b>Clinical Trial Registration:</b> NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov).</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"207-213"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9790150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the impact of caring for an individual with neurogenic orthostatic hypotension: a qualitative study. 探讨神经源性直立性低血压患者护理的影响:一项定性研究。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0016
Katy Gallop, Ngan Pham, Grant Maclaine, Emma Saunders, Bonnie Black, Sarah Acaster

Aim: This study aimed to explore the impact of caring for an individual with neurogenic orthostatic hypotension (nOH). Methods: Informal caregivers of individuals with nOH and either Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies completed semi-structured interviews. Data were analyzed using thematic analysis; the identified concepts were used to develop a conceptual model. Results: Twenty informal caregivers were interviewed. Analysis identified several areas of caregiver impact due to nOH including impact on their time, particularly a need to supervise the patient to prevent falls as well as a lack of freedom and negative physical, work and social impacts. Many reported negative emotional impacts, including worry, stress or fear about the patient falling, depression and frustration. The conceptual model shows the relationships between concepts. Conclusion: The results highlight the wide-ranging impact of nOH, and the specific impact of the fear of falls on informal caregivers' lives.

目的:本研究旨在探讨护理对神经源性直立性低血压(nOH)患者的影响。方法:nOH合并帕金森病、多系统萎缩、纯自主神经衰竭或路易体痴呆患者的非正式护理人员完成半结构化访谈。数据采用专题分析;确定的概念被用来开发一个概念模型。结果:对20名非正式护理人员进行了访谈。分析确定了nOH对护理人员的几个方面的影响,包括对他们时间的影响,特别是需要监督患者以防止跌倒,以及缺乏自由和负面的身体,工作和社会影响。许多人报告了负面的情绪影响,包括担心、压力或对病人摔倒的恐惧、抑郁和沮丧。概念模型显示了概念之间的关系。结论:研究结果突出了nOH的广泛影响,以及对跌倒的恐惧对非正式照顾者生活的具体影响。
{"title":"Exploring the impact of caring for an individual with neurogenic orthostatic hypotension: a qualitative study.","authors":"Katy Gallop,&nbsp;Ngan Pham,&nbsp;Grant Maclaine,&nbsp;Emma Saunders,&nbsp;Bonnie Black,&nbsp;Sarah Acaster","doi":"10.2217/nmt-2022-0016","DOIUrl":"https://doi.org/10.2217/nmt-2022-0016","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to explore the impact of caring for an individual with neurogenic orthostatic hypotension (nOH). <b>Methods:</b> Informal caregivers of individuals with nOH and either Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies completed semi-structured interviews. Data were analyzed using thematic analysis; the identified concepts were used to develop a conceptual model. <b>Results:</b> Twenty informal caregivers were interviewed. Analysis identified several areas of caregiver impact due to nOH including impact on their time, particularly a need to supervise the patient to prevent falls as well as a lack of freedom and negative physical, work and social impacts. Many reported negative emotional impacts, including worry, stress or fear about the patient falling, depression and frustration. The conceptual model shows the relationships between concepts. <b>Conclusion:</b> The results highlight the wide-ranging impact of nOH, and the specific impact of the fear of falls on informal caregivers' lives.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"191-201"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10041184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cross-sectoral collaboration among hospital professionals on rehabilitation for patients with neuromuscular diseases. 医院专业人员在神经肌肉疾病患者康复方面的跨部门合作。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0024
Charlotte Handberg, Ulla Werlauff

Introduction: Living with a neuromuscular disease often leads to a need for specialized rehabilitation due to the complexity and progression of the diseases. Aim: To investigate cross-sectoral collaboration on rehabilitation for patients with neuromuscular diseases among hospital professionals to inform future targeted rehabilitation services. Patients & methods: The design was qualitative using the interpretive description methodology and the theoretical lens of symbolic interactionism. Ethnographic fieldwork was conducted, and 50 hospital professionals included, 19 of whom were interviewed. Results & conclusion: The results emphasize the importance of relations when collaborating across sectors. The professionals acted and made choices in relation to dilemmas and influences of diagnosis and progression, professional demarcations in multiprofessional teams, and cross-sectoral collaboration toward a mutual goal.

由于疾病的复杂性和进展,神经肌肉疾病患者往往需要专门的康复治疗。目的:探讨医院专业人员在神经肌肉疾病患者康复方面的跨部门合作,为未来有针对性的康复服务提供依据。患者与方法:本设计采用解释性描述方法和符号互动主义的理论视角进行定性设计。进行了民族志实地调查,包括50名医院专业人员,其中19人接受了采访。结果与结论:结果强调了跨部门合作时关系的重要性。专业人员在诊断和进展的困境和影响、多专业团队的专业划分以及为共同目标而进行的跨部门合作方面采取行动并做出选择。
{"title":"Cross-sectoral collaboration among hospital professionals on rehabilitation for patients with neuromuscular diseases.","authors":"Charlotte Handberg,&nbsp;Ulla Werlauff","doi":"10.2217/nmt-2022-0024","DOIUrl":"https://doi.org/10.2217/nmt-2022-0024","url":null,"abstract":"<p><p><b>Introduction:</b> Living with a neuromuscular disease often leads to a need for specialized rehabilitation due to the complexity and progression of the diseases. <b>Aim:</b> To investigate cross-sectoral collaboration on rehabilitation for patients with neuromuscular diseases among hospital professionals to inform future targeted rehabilitation services. <b>Patients & methods:</b> The design was qualitative using the interpretive description methodology and the theoretical lens of symbolic interactionism. Ethnographic fieldwork was conducted, and 50 hospital professionals included, 19 of whom were interviewed. <b>Results & conclusion:</b> The results emphasize the importance of relations when collaborating across sectors. The professionals acted and made choices in relation to dilemmas and influences of diagnosis and progression, professional demarcations in multiprofessional teams, and cross-sectoral collaboration toward a mutual goal.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"161-175"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The amyloid-β pathway in Alzheimer's disease: a plain language summary. 阿尔茨海默病中的淀粉样蛋白-β通路:通俗易懂的摘要。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2023-06-01 Epub Date: 2023-03-30 DOI: 10.2217/nmt-2022-0037
Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L Masters, Min Cho, Lars Lannfelt, Jeffrey L Cummings, Andrea Vergallo

What is this summary about?: This plain language summary of an article published in Molecular Psychiatry, reviews the evidence supporting the role of the amyloid-β (Aβ) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the Aβ pathway in the early stages of the disease.

Why is this important?: Aβ is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of Aβ plaques is a hallmark of AD. However, smaller, soluble aggregates of Aβ - including Aβ protofibrils - also play a role in the disease. Because Aβ-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the Aβ protein and its role in AD, summarizing the evidence showing that altered Aβ clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD.

What are the key takeaways?: The physiological balance of brain Aβ levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that Aβ has a central role in driving AD progression. A better understanding of the Aβ pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches.

这篇摘要是关于什么的?:这篇发表在《分子精神病学》(Molecular Psychiatry)上的文章的摘要用通俗易懂的语言回顾了支持淀粉样蛋白-β(Aβ)通路的作用及其在阿尔茨海默病(AD)中失调的证据,并强调了在疾病早期阶段针对 Aβ 通路用药的基本原理:Aβ 是一种蛋白质片段(或肽),有多种存在形式,因其大小、形状/结构、溶解度和与疾病的相关性而各不相同。Aβ 斑块的累积是注意力缺失症的标志。然而,较小的可溶性Aβ聚集体(包括Aβ原纤维)也在疾病中发挥作用。由于与 Aβ 相关的疾病机制十分复杂,因此,AD 的诊断、治疗和管理应反映并以该领域的最新科学知识和研究成果为指导。本文介绍了Aβ蛋白及其在AD中的作用,总结了有证据显示大脑中Aβ清除的改变可能会导致该蛋白的失衡、毒性积聚和错误折叠--引发一连串的细胞、分子和系统事件,最终导致AD:AD背景下大脑Aβ水平的生理平衡非常复杂。尽管还有许多问题没有答案,但越来越多的证据表明,Aβ在推动AD发展中起着核心作用。更好地了解 Aβ 通路的生物学特性将有助于确定 AD 的最佳治疗靶点,并为治疗方法提供依据。
{"title":"The amyloid-β pathway in Alzheimer's disease: a plain language summary.","authors":"Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L Masters, Min Cho, Lars Lannfelt, Jeffrey L Cummings, Andrea Vergallo","doi":"10.2217/nmt-2022-0037","DOIUrl":"10.2217/nmt-2022-0037","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This plain language summary of an article published in <i>Molecular Psychiatry</i>, reviews the evidence supporting the role of the amyloid-β (Aβ) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the Aβ pathway in the early stages of the disease.</p><p><strong>Why is this important?: </strong>Aβ is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of Aβ plaques is a hallmark of AD. However, smaller, soluble aggregates of Aβ - including Aβ protofibrils - also play a role in the disease. Because Aβ-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the Aβ protein and its role in AD, summarizing the evidence showing that altered Aβ clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD.</p><p><strong>What are the key takeaways?: </strong>The physiological balance of brain Aβ levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that Aβ has a central role in driving AD progression. A better understanding of the Aβ pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"141-149"},"PeriodicalIF":2.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/70/nmt-13-141.PMC10334247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9775627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study. 可穿戴活动监测仪支持神经退行性疾病的身体活动干预:可行性研究
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0028
Hai-Jung Steffi Shih, Lori Quinn, Philippa Morgan-Jones, Katrina Long, Abigail R Schreier, Ciaran P Friel

Aim: To evaluate the feasibility of using activity monitors in a physical activity (PA) intervention in people with Parkinson's (PD) and Huntington's disease (HD). Materials & methods: People with early-stage PD (n = 13) and HD (n = 14) enrolled in a 4-month coaching program, wore a Fitbit, and were guided through a behavioral intervention to facilitate PA uptake. Wear time, wear habits and activity metrics (e.g., steps) were analyzed. Results: Retention rate was 85% and participants had an average 92.3% (±9.2) valid wear days. Daily wear time was 18.4 (±4.5) h. Day & night Fitbit wearers showed improvements in steps (d = 1.02) and MET×min/week (d = 0.69) compared with day-only wearers. Conclusion: Implementing wearables in a coaching intervention was feasible and provided insights into PA behavior.

目的:评价活动监测仪在帕金森病(PD)和亨廷顿病(HD)患者身体活动(PA)干预中的可行性。材料与方法:患有早期PD (n = 13)和HD (n = 14)的患者参加了为期4个月的指导计划,佩戴Fitbit,并通过行为干预指导促进PA的吸收。分析了佩戴时间、佩戴习惯和活动指标(例如,步数)。结果:保留率为85%,平均有效佩戴天数为92.3%(±9.2)天。每天佩戴时间为18.4(±4.5)小时。与只佩戴Fitbit的人相比,白天和晚上佩戴者的步数(d = 1.02)和MET×min/周(d = 0.69)均有所改善。结论:在教练干预中实施可穿戴设备是可行的,并提供了对PA行为的见解。
{"title":"Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study.","authors":"Hai-Jung Steffi Shih,&nbsp;Lori Quinn,&nbsp;Philippa Morgan-Jones,&nbsp;Katrina Long,&nbsp;Abigail R Schreier,&nbsp;Ciaran P Friel","doi":"10.2217/nmt-2022-0028","DOIUrl":"https://doi.org/10.2217/nmt-2022-0028","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the feasibility of using activity monitors in a physical activity (PA) intervention in people with Parkinson's (PD) and Huntington's disease (HD). <b>Materials & methods:</b> People with early-stage PD (n = 13) and HD (n = 14) enrolled in a 4-month coaching program, wore a Fitbit, and were guided through a behavioral intervention to facilitate PA uptake. Wear time, wear habits and activity metrics (e.g., steps) were analyzed. <b>Results:</b> Retention rate was 85% and participants had an average 92.3% (±9.2) valid wear days. Daily wear time was 18.4 (±4.5) h. Day & night Fitbit wearers showed improvements in steps (d = 1.02) and MET×min/week (d = 0.69) compared with day-only wearers. <b>Conclusion:</b> Implementing wearables in a coaching intervention was feasible and provided insights into PA behavior.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"177-189"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users. 患者报告的结果是肌内干扰素β-1a使用者疾病失能的最强预测因子。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0008
Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman

Introduction: Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). Materials: 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. Results: PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). Conclusion: Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.

患者报告结果(PROs)是多发性硬化症(pwMS)患者常规临床护理的重要指标。材料:从纽约州多发性硬化症协会中回顾性纳入干扰素-β-1a (IFN-β-1a)治疗的646例pwMS。收集入组时和3年随访时的临床和PRO数据。根据年龄、扩展残疾状态量表(EDSS)评分和疾病持续时间对病情稳定和残疾恶化的PwMS进行1:1匹配。根据试验标准确定残疾恶化。结果:未来EDSS恶化的PwMS有更高的基线和随访时间-25英尺步行(6.6 vs 5.5 s;9.1 vs 5.5 s;结论:重度疲劳和下肢功能受限是pwMS患者未来残疾恶化的重要预测因素。
{"title":"Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users.","authors":"Caila B Vaughn,&nbsp;Katelyn S Kavak,&nbsp;Dejan Jakimovski,&nbsp;Natasha Qutab,&nbsp;Robin Avila,&nbsp;Megan Vignos,&nbsp;Bianca Weinstock-Guttman","doi":"10.2217/nmt-2022-0008","DOIUrl":"https://doi.org/10.2217/nmt-2022-0008","url":null,"abstract":"<p><p><b>Introduction:</b> Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). <b>Materials:</b> 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. <b>Results:</b> PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). <b>Conclusion:</b> Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"151-159"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9672864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
5-HT1A agonists for levodopa-induced dyskinesia in Parkinson's disease. 5-HT1A激动剂治疗帕金森病左旋多巴诱导的运动障碍。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0039
Jawad Al-Kassmy, Christine Sun, Philippe Huot

Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT1A) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT1A agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT1A agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.

左旋多巴是治疗帕金森病(PD)症状最有效的药物。然而,左旋多巴诱导的运动障碍仍然是一个重要的并发症,在治疗几年后表现出来,治疗选择仍然有限。几种5-羟色胺1A (5-HT1A)受体激动剂具有不同程度的疗效和在其他部位的相互作用,已经在临床中进行了测试。测试5-HT1A激动剂的临床试验在缓解运动障碍方面得出了不一致的结果,特别是观察到的抗运动障碍益处往往伴随着对运动功能的不利影响。在这篇文章中,我们总结和分析了5-HT1A激动剂在帕金森病患者运动障碍中的各种临床试验,并对这类药物在帕金森病患者中的未来发展提出了展望。
{"title":"5-HT<sub>1A</sub> agonists for levodopa-induced dyskinesia in Parkinson's disease.","authors":"Jawad Al-Kassmy,&nbsp;Christine Sun,&nbsp;Philippe Huot","doi":"10.2217/nmt-2022-0039","DOIUrl":"https://doi.org/10.2217/nmt-2022-0039","url":null,"abstract":"<p><p>Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT<sub>1A</sub>) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT<sub>1A</sub> agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT<sub>1A</sub> agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"101-112"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9575481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurodegenerative disease management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1